Research programme: metabolic and lipid disorder therapeutics - Spherix

Drug Profile

Research programme: metabolic and lipid disorder therapeutics - Spherix

Alternative Names: SPX 100; SPX 10624258; SPX 723; SPX 7233801; SPX 8522876; SPX 8818309; SPX 8818440; SPX-106; SPX-106T

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Kentucky Research Foundation
  • Developer Spherix
  • Class Hexoses; Small molecules
  • Mechanism of Action Iron chelating agents; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Abdominal aortic aneurysm; Atherosclerosis; Diabetes mellitus; Dyslipidaemias; Metabolic syndrome; Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Abdominal-aortic-aneurysm in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top